Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation
Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation
$200.00
AveXis co-founder and CSO Brian Kaspar and his brother are no longer with Novartis, the Swiss manufacturer who acquired AveXis and its Zolgensma drug in 2018. After disclosing data manipulation to the FDA earlier this year about Zolgensma filings, Novartis announced two employees would exit the company.
Publisher: Scrip
- Description
Novartis announced in August that the company was in the process of “exiting a small number of AveXis scientists” involved in data manipulation in the filings for Zolgensma, their spinal muscular atrophy therapy. On August 14 they announced that AveXis co-founder and chief scientific officer, Brian Kaspar, and his brother were leaving the company. They have been replaced by Page Bouchard, a 27-year biopharmaceutical industry veteran and recent global head of preclinical safety for Novartis Institutes of Biomedical Research. This Scrip story provides details on the issues surrounding Zolgensma and important background on the players involved.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Big Pharma Licensing Trends, 2014–18 
Sign up to the